Autoimmune Diseases  >>  Inflectra (infliximab-dyyb)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
NCT01217086: Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)

Checkmark EULAR 2014: Rheumatoid Arthritis
May 2014 - May 2014: EULAR 2014: Rheumatoid Arthritis
Checkmark PLANETRA (ACR/ARHP 2013)
Oct 2013 - Oct 2013: PLANETRA (ACR/ARHP 2013)
Completed
3
617
RoW
Infliximab, remicade
Celltrion
Rheumatoid Arthritis
11/11
07/12
NCT01571219 / 2011-004468-31: An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1

Completed
3
302
RoW
Infliximab
Celltrion
Rheumatoid Arthritis
07/13
07/13

Download Options